S Ahmed, G Thomas, M Ghoussaini, CS Healey, MK Humphreys, R Platte, J Morrison, M Maranian, KA Pooley, R Luben, D Eccles, DG Evans, O Fletcher, N Johnson, I dos Santos Silva, J Peto, MR Stratton, N Rahman, K Jacobs, R Prentice, GL Anderson, A Rajkovic, JD Curb, RG Ziegler, CD Berg, SS Buys, CA McCarty, HS Feigelson, EE Calle, MJ Thun, WR Diver, S Bojesen, BG Nordestgaard, H Flyger, T Dörk, P Schürmann, P Hillemanns, JH Karstens, NV Bogdanova, NN Antonenkova, IV Zalutsky, M Bermisheva, S Fedorova, E Khusnutdinova, SEARCH, D Kang, K-Y Yoo, DY Noh, S-H Ahn, P Devilee, CJ van Asperen, RAEM Tollenaar, C Seynaeve, M Garcia-Closas, J Lissowska, L Brinton, B Peplonska, H Nevanlinna, T Heikkinen, K Aittomäki, C Blomqvist, JL Hopper, MC Southey, L Smith, AB Spurdle, MK Schmidt, A Broeks, RR van Hien, S Cornelissen, RL Milne, G Ribas, A González-Neira, J Benitez, RK Schmutzler, B Burwinkel, CR Bartram, A Meindl, H Brauch, C Justenhoven, U Hamann, GENICA Consortium, J Chang-Claude, R Hein, S Wang-Gohrke, A Lindblom, S Margolin, A Mannermaa, V-M Kosma, V Kataja, JE Olson, X Wang, Z Fredericksen, GG Giles, G Severi, L Baglietto, DR English, SE Hankinson, DG Cox, P Kraft, LJ Vatten, K Hveem, M Kumle, A Sigurdson, M Doody, P Bhatti, BH Alexander, MJ Hooning, AMW van den Ouweland, RA Oldenburg, M Schutte, P Hall, K Czene, J Liu, Y Li, A Cox, G Elliott, I Brock, MWR Reed, C-Y Shen, J-C Yu, G-C Hsu, S-T Chen, H Anton-Culver, A Ziogas, IL Andrulis, JA Knight, kConFab, Australian Ovarian Cancer Study Group, J Beesley, EL Goode, F Couch, G Chenevix-Trench, RN Hoover, BAJ Ponder, DJ Hunter, PDP Pharoah, AM Dunning, SJ Chanock, DF Easton
Genome-wide association studies (GWAS) have identified seven breast cancer susceptibility loci, but these explain only a small fraction of the familial risk of the disease. Five of these loci were identified through a two-stage GWAS involving 390 familial cases and 364 controls in the first stage, and 3,990 cases and 3,916 controls in the second stage. To identify additional loci, we tested over 800 promising associations from this GWAS in a further two stages involving 37,012 cases and 40,069 controls from 33 studies in the CGEMS collaboration and Breast Cancer Association Consortium. We found strong evidence for additional susceptibility loci on 3p (rs4973768: per-allele OR = 1.11, 95% CI = 1.08-1.13, P = 4.1 x 10(-23)) and 17q (rs6504950: per-allele OR = 0.95, 95% CI = 0.92-0.97, P = 1.4 x 10(-8)). Potential causative genes include SLC4A7 and NEK10 on 3p and COX11 on 17q.